Yatharth Hospital
YATHARTH NSE
Yatharth Hospital
HealthcareNSE: YATHARTH BSE: 543950 Healthcare Services
Key Fundamentals
MicrocapHospitalsHealthcare ServicesMarket Cap
₹9,276 Cr
Volatility
Moderate
P/E Ratio
51.4
EBITDA
₹292 Cr
Return on Equity
7.97%
Debt to Equity
0.15
Book Value
₹184.79
EPS
₹14.66
52W High
₹1,024.85
52W Low
₹538.25
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has delivered good profit growth of 57.4% CAGR over last 5 years
- Company's working capital requirements have reduced from 102 days to 80.1 days
Weaknesses
1- Company has a low return on equity of 12.1% over last 3 years.
Growth Rate
Revenue Growth
34.62% lower than
3Y
Net Income Growth
31% lower than
3Y
Cash Flow Change
—
ROE
-39.11% lower than
3Y
ROCE
-37.63% higher than
3Y
EBITDA Margin (Avg.)
-10.16% higher than
3Y
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 69d agoAI opinion · based on fundamentals
Risk high
Yatharth Hospital & Trauma Care Services is a mid-cap healthcare company with a market cap of Rs 8,296 Cr trading at a PE of 49x. The company has delivered strong revenue growth of 41% CAGR over 5 years and profit growth of 57% CAGR over the same period, though its return on equity has moderated to 10% in the last year from a 5-year average of 14%.
Bull Case 8
- Exceptional 5-year compounded profit growth of 57% CAGR demonstrates strong operating leverage and scaling ability
- Compounded sales growth of 41% CAGR over 5 years and 36% over 3 years indicates sustained revenue momentum in a growing healthcare market
- TTM revenue growth remains robust at 40%, showing no meaningful deceleration from the 3-year trend of 36%
- Working capital days have improved from 102 days to 80.1 days, reflecting better operational efficiency and cash conversion
- Stock has delivered 50% returns over the past 1 year, indicating strong market confidence in the growth trajectory
- TTM profit growth of 36% remains healthy and broadly in line with the 3-year CAGR of 39%
- Company is expected to deliver a good quarter ahead, suggesting near-term earnings visibility remains intact
- Price-to-book ratio of 4.68x is not extreme for a high-growth healthcare platform, suggesting the market is pricing in continued compounding
Bear Case 8
- PE ratio of 49x is elevated and leaves little margin of safety if growth decelerates from current 36-40% levels
- Return on equity has declined from a 5-year average of 14% to just 10% in the last year, signaling potential dilution of capital efficiency as the company expands
- Zero dividend yield despite repeated profitability means shareholders rely entirely on capital appreciation for returns
- 3-year ROE of only 12% is below the 15%+ threshold typically expected for a company commanding a 49x PE multiple
- Debt-to-equity ratio is not disclosed, creating uncertainty about the leverage profile funding the aggressive expansion
- Profit growth has decelerated from 57% CAGR over 5 years to 39% over 3 years and 36% TTM, suggesting the rate of earnings expansion may be plateauing
- Limited listed history with no available 3-year, 5-year, or 10-year stock CAGR data makes it difficult to assess long-term shareholder value creation
- At Rs 8,296 Cr market cap with a 49x PE, any quarterly miss or margin compression could trigger a sharp de-rating given the premium valuation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 69d ago Positives 1
- Rs 100 Cr Gurugram acquisition Jun 12
Yatharth Hospital completed acquisition of Gurugram assets worth Rs 100 Cr through subsidiary AKS Medical, expanding its geographic footprint in the NCR region.
Neutral 1
- No promoter share encumbrance Jun 30
Promoters held 5,37,62,672 shares as on March 31, 2026 with zero encumbrance during FY26, indicating no pledging pressure on promoter holdings.
TL;DR: Yatharth Hospital is in expansion mode with a Rs 100 Cr asset acquisition in Gurugram signaling capacity growth in the NCR market. Promoter holdings remain unencumbered, reflecting financial discipline. No visible headwinds from recent news flow. The trend appears constructive with the company investing in growth while maintaining a clean balance sheet posture.
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 155 | 171 | 167 | 178 | 212 | 218 | 219 | 232 | 258 | 279 | 320 | 342 | 393 |
| Expenses | 113 | 126 | 120 | 131 | 158 | 163 | 164 | 175 | 193 | 215 | 246 | 262 | 301 |
| Operating Profit | 41 | 46 | 46 | 47 | 54 | 55 | 55 | 57 | 64 | 65 | 74 | 80 | 92 |
| OPM % | 27% | 27% | 28% | 26% | 25% | 25% | 25% | 25% | 25% | 23% | 23% | 23% | 23% |
| Other Income | 1 | 4 | 5 | 6 | 4 | 3 | 4 | 5 | 9 | 9 | 8 | 7 | 4 |
| Interest | 6 | 3 | 0 | 0 | 3 | 2 | 2 | 1 | 0 | 0 | 1 | 5 | 7 |
| Depreciation | 7 | 7 | 8 | 8 | 11 | 16 | 17 | 13 | 15 | 19 | 24 | 30 | 28 |
| PBT | 29 | 40 | 44 | 44 | 43 | 40 | 40 | 49 | 59 | 55 | 57 | 52 | 61 |
| Tax % | 35% | 30% | 33% | 13% | 29% | 23% | 24% | 20% | 28% | 25% | 25% | 14% | 26% |
| Net Profit | 19 | 28 | 29 | 38 | 30 | 31 | 30 | 39 | 42 | 41 | 43 | 45 | 45 |
| EPS in Rs | 2.91 | 3.21 | 3.44 | 4.47 | 3.54 | 3.61 | 3.16 | 4.02 | 4.36 | 4.28 | 4.71 | 4.93 | 4.88 |
Profit & Loss
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 71 | 78 | 91 | 136 | 215 | 375 | 478 | 635 | 860 | 1,207 | 1,334 |
| Expenses | 53 | 60 | 71 | 98 | 147 | 263 | 343 | 453 | 635 | 915 | 1,024 |
| Operating Profit | 18 | 18 | 20 | 38 | 68 | 112 | 135 | 182 | 225 | 292 | 310 |
| OPM % | 25% | 24% | 22% | 28% | 32% | 30% | 28% | 29% | 26% | 24% | 23% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 16 | 16 | 26 | 29 |
| Interest | 6 | 5 | 7 | 20 | 20 | 23 | 23 | 11 | 12 | 7 | 13 |
| Depreciation | 7 | 6 | 8 | 21 | 21 | 28 | 28 | 29 | 57 | 88 | 101 |
| PBT | 5 | 8 | 5 | -2 | 28 | 63 | 88 | 157 | 172 | 224 | 225 |
| Tax % | 41% | 23% | 21% | -18% | 30% | 30% | 25% | 27% | 24% | 24% | — |
| Net Profit | 3 | 6 | 4 | -2 | 20 | 44 | 66 | 114 | 131 | 170 | 174 |
| EPS in Rs | 2.21 | 3.75 | 2.43 | -0.79 | 11.09 | 6.74 | 10.04 | 13.33 | 13.55 | 18.2 | 18.8 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 16 | 16 | 16 | 16 | 66 | 66 | 86 | 96 | 96 |
| Reserves | 29 | 41 | 39 | 38 | 56 | 51 | 117 | 788 | 1,509 | 1,684 |
| Borrowings | 85 | 125 | 175 | 194 | 193 | 264 | 267 | 85 | 12 | 264 |
| Other Liabilities | 10 | 11 | 26 | 39 | 43 | 45 | 36 | 60 | 114 | 237 |
| Total Liabilities | 138 | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 | 2,282 |
| Fixed Assets | 54 | 53 | 164 | 189 | 251 | 303 | 299 | 442 | 605 | 1,250 |
| CWIP | 64 | 110 | 65 | 62 | 0 | 0 | 0 | 0 | 222 | 102 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74 | 2 |
| Other Assets | 20 | 30 | 27 | 36 | 58 | 123 | 187 | 577 | 829 | 928 |
| Total Assets | 138 | 193 | 257 | 287 | 309 | 426 | 486 | 1,019 | 1,731 | 2,282 |
Cash Flow
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 25 | 17 | 17 | 39 | 44 | 60 | 64 | -3 | 150 | 205 |
| Investing | -50 | -51 | -78 | -43 | -21 | -52 | -20 | -226 | -420 | -598 |
| Financing | 26 | 43 | 47 | 5 | -19 | -1 | -18 | 304 | 520 | 254 |
| Net Cash Flow | 1 | 9 | -13 | 1 | 3 | 7 | 26 | 75 | 249 | -140 |
| Free Cash Flow | 24 | 16 | -60 | -4 | 24 | 21 | 44 | -96 | -161 | -112 |
| CFO/OP | 148 | 103 | 99 | 109 | 67 | 65 | 75 | 22 | 78 | 98 |
Ratios
| Particulars | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 58 | 44 | 48 | 45 | 62 | 83 | 82 | 131 | 128 | 113 |
| Inventory Days | 47 | 42 | 88 | 72 | — | — | — | — | — | 32 |
| Days Payable | 127 | 106 | 490 | 347 | — | — | — | — | — | 171 |
| Cash Conversion Cycle | -22 | -20 | -354 | -229 | 62 | 83 | 82 | 131 | 128 | -26 |
| Working Capital Days | 44 | 29 | -75 | -89 | -18 | 0 | 29 | 118 | 109 | 80 |
| ROCE % | — | 8% | 6% | 7% | 18% | 26% | 27% | 24% | 14% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Yatharth Hospital insights
42 extracted metrics + investor summaries across FY17–FY26.
Documents
1
Clarification sought from Yatharth Hospital & Trauma Care Services Ltd
28 Aug - Exchange has sought clarification from Yatharth Hospital & Trauma Care Services Ltd on August 28, 2026, with reference to news appeared in https://www.moneycontrol.com/ dated 2026-08-28 … 28 Aug - Exchange has sought clarification from Yatharth Hospital & Trauma Care Services Ltd on August 28, 2026, with reference to news appeared in https://www.moneycontrol.com/ dated 2026-08-28 …
2
Compliances-Reg.24(A)-Annual Secretarial Compliance
1 May - Submitted Annual Secretarial Compliance Report for FY ended March 31, 2026; no non-compliances observed. 1 May - Submitted Annual Secretarial Compliance Report for FY ended March 31, 2026; no non-compliances observed.
3
Compliances-Reg.24(A)-Annual Secretarial Compliance
1 May - Submitted Annual Secretarial Compliance Report for FY ended March 31, 2026; no non-compliances observed. 1 May - Submitted Annual Secretarial Compliance Report for FY ended March 31, 2026; no non-compliances observed.
5
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
10 Apr - Yatharth Hospital confirms it is not a large corporate; outstanding borrowing was Rs. 230 crore as of March 31, 2026. 10 Apr - Yatharth Hospital confirms it is not a large corporate; outstanding borrowing was Rs. 230 crore as of March 31, 2026.
Frequently Asked Questions about Yatharth Hospital
What does Yatharth Hospital & Trauma Care Services Ltd do?
Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals at Noida, Greater Noida, and Noida Extension, Uttar Pradesh.[1]
Where is Yatharth Hospital & Trauma Care Services Ltd (YATHARTH) listed?
Yatharth Hospital & Trauma Care Services Ltd trades as YATHARTH on the NSE and under code 543950 on the BSE.
Which sector does Yatharth Hospital & Trauma Care Services Ltd belong to?
Yatharth Hospital & Trauma Care Services Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Yatharth Hospital & Trauma Care Services Ltd?
Yatharth Hospital & Trauma Care Services Ltd has a market capitalisation of ₹9,276 Cr, which places it in the Mid Cap band.
What is the PE ratio of Yatharth Hospital & Trauma Care Services Ltd?
Yatharth Hospital & Trauma Care Services Ltd trades at a PE ratio of 51.40, on earnings per share of ₹14.66, against a book value of ₹184.79 per share.
What is the 52-week high and low of Yatharth Hospital & Trauma Care Services Ltd?
Over the last 52 weeks Yatharth Hospital & Trauma Care Services Ltd has traded between ₹538.25 and ₹1,024.85.
Does Yatharth Hospital & Trauma Care Services Ltd pay dividends?
Yatharth Hospital & Trauma Care Services Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Yatharth Hospital & Trauma Care Services Ltd?
Yatharth Hospital & Trauma Care Services Ltd reported a return on equity of 7.97%. Its debt-to-equity ratio is 0.15.
Company Information
Incorporated in 2008, Yatharth Hospital and Trauma Care Services Limited is a multi-care hospitals at Noida, Greater Noida, and Noida Extension, Uttar Pradesh.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/YATHARTH.md for Yatharth Hospital & Trauma Care Services Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.